What it's for (Indications)
- This fixed-dose combination medication, containing amlodipine, indapamide, and perindopril, is indicated for the treatment of essential hypertension in adult patients.
- It is specifically formulated for individuals whose blood pressure is not adequately controlled with monotherapy or dual therapy, or for patients who are already controlled on the individual components given concurrently at the same dose levels.
- The synergistic action of its three active ingredients—a calcium channel blocker, a thiazide-like diuretic, and an ACE inhibitor—provides comprehensive blood pressure control by targeting various physiological pathways involved in hypertension.
- This approach aims to achieve optimal therapeutic outcomes and improve patient adherence through a simplified regimen.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of amlodipine + indapamide + perindopril must be carefully individualized based on the patient's existing therapeutic regimen, clinical response, renal function, and hepatic function. This fixed-dose combination is typically administered orally once daily, preferably in the morning before a meal. It is crucial to emphasize that this combination is generally not recommended for the initiation of antihypertensive therapy but rather for maintenance treatment in patients already adequately controlled on the individual components. Dose adjustments should always be made under strict medical supervision. Particular caution is advised when dosing elderly patients or those with moderate renal or hepatic impairment, where lower starting doses or meticulous monitoring may be necessary to prevent adverse effects. The maximum recommended daily dose should not be exceeded. |
Safety & Warnings
Common Side Effects
- Common side effects associated with amlodipine + indapamide + perindopril may include, but are not limited to, dizziness, headache, fatigue, and peripheral edema (a common occurrence with amlodipine).
- Gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and dyspepsia can also occur.
- Due to indapamide, electrolyte abnormalities like hypokalemia, hyponatremia, and hyperuricemia are possible, necessitating regular monitoring.
- Perindopril, an ACE inhibitor, frequently causes a persistent dry cough.
- Other potential adverse reactions include palpitations, somnolence, muscle cramps, and skin rashes.
- More serious, albeit less common, side effects include symptomatic hypotension, syncope, angioedema (potentially life-threatening, particularly with perindopril), hyperkalemia, significant renal impairment, and hepatic dysfunction.
- Patients should be advised to promptly report any severe, persistent, or concerning adverse reactions to their healthcare provider.
Serious Warnings
- Black Box Warning: **WARNING: FETAL TOXICITY** Perindopril, a critical component of this fixed-dose combination, belongs to the class of Angiotensin-Converting Enzyme (ACE) inhibitors. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, amlodipine + indapamide + perindopril should be discontinued as soon as possible. There have been numerous reports of significant fetal abnormalities, including oligohydramnios, fetal lung hypoplasia, skeletal deformations, anuria, and death, when ACE inhibitors are used during the second and third trimesters of pregnancy. Even exposure limited to the first trimester carries potential risks for congenital malformations. Infants exposed to ACE inhibitors in utero should be closely observed for hypotension, oliguria, and hyperkalemia. Use of ACE inhibitors during pregnancy is absolutely contraindicated. Healthcare providers should counsel women of childbearing potential about the profound risks of exposure to this medication during pregnancy and the paramount importance of using effective contraception. If pregnancy occurs, the medication should be immediately discontinued and appropriate alternative antihypertensive therapy initiated after medical consultation.
- Patients receiving amlodipine + indapamide + perindopril require close monitoring for several critical conditions.
- Severe hypotension, leading to syncope or other complications, may occur, particularly in volume-depleted patients, those with severe heart failure, or patients undergoing dialysis; careful titration and monitoring are essential.
- Angioedema, a potentially life-threatening hypersensitivity reaction involving swelling of the face, extremities, lips, tongue, glottis, and/or larynx, can develop at any time during treatment with perindopril; immediate medical intervention is critical.
- This medication should be used with extreme caution in patients with severe aortic stenosis or hypertrophic obstructive cardiomyopathy due to the risk of reduced cardiac output.
- Renal function should be routinely assessed, especially in patients with pre-existing renal impairment, as ACE inhibitors can exacerbate or induce renal dysfunction.
- Indapamide can induce significant electrolyte imbalances, including hypokalemia, hyponatremia, and hypochloremic alkalosis, mandating regular electrolyte monitoring.
- Hyperkalemia is also a risk, particularly in patients with renal impairment, diabetes, or those concurrently using potassium-sparing diuretics or potassium supplements.
- Concomitant use with aliskiren in diabetic or renally impaired patients is contraindicated.
- Use during pregnancy is strictly contraindicated due to severe fetal risk (refer to Black Box Warning).
How it Works (Mechanism of Action)
This combination medication leverages three distinct pharmacological mechanisms to achieve potent antihypertensive effects. Perindopril, an Angiotensin-Converting Enzyme (ACE) inhibitor, works by blocking the enzymatic conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This action leads to several beneficial effects: vasodilation, decreased aldosterone secretion (which reduces sodium and water reabsorption), and inhibition of bradykinin degradation, further promoting vasodilation. Amlodipine, a dihydropyridine calcium channel blocker, selectively inhibits the transmembrane influx of calcium ions into vascular smooth muscle cells and, to a lesser extent, cardiac muscle. This results in the relaxation of arterial smooth muscle, leading to peripheral vasodilation and a reduction in systemic vascular resistance. Indapamide, a thiazide-like diuretic, exerts its primary action in the cortical diluting segment of the nephron, where it inhibits the reabsorption of sodium and chloride ions. This increases the excretion of sodium, chloride, and water, contributing to a reduction in plasma volume and blood pressure. Indapamide also possesses a direct vasodilatory effect, further aiding in its antihypertensive action. The combined effects of these three agents result in comprehensive and sustained blood pressure reduction.
Commercial Brands (Alternatives)
No other brands found for this formula.